SCHEMBL7601367

SCHEMBL7601367

O=C(O)c1nc(-c2ccc(-c3ccccc3)cc2)nc2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 4/20 0.54
ADORA3 P0DMS8 1/20 0.54
ABCC1 P33527 1/20 0.54
DHODH Q02127 3/20 0.53
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
SIRT5 Q9NXA8 2/20 0.52
ALDH1A1 P00352 3/20 0.52
MAPT P10636 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
KDM4E B2RXH2 3/20 0.50
ATM Q13315 1/20 0.50
TSPO P30536 1/20 0.50
PRNP P04156 1/20 0.50
TACR3 P29371 1/20 0.50
TP53 P04637 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
HPGD P15428 1/20 0.50
HIF1A Q16665 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5781008 0.96 ABCG2 (0.57) ABCG2ADORA3ABCC1MEN1KMT2A
Dimethylamine SCHEMBL4104002 0.90 ABCG2 (0.55) ABCG2ADORA3ABCC1MEN1KMT2A
SCHEMBL16039146 0.88 CYP1A1 (0.60) ABCG2ADORA3MEN1KMT2AALDH1A1
SCHEMBL16039656 0.88 MAPT (0.59) ABCG2ADORA3ABCC1MEN1KMT2A
SCHEMBL5795510 0.88 CYP1B1 (0.60) ABCG2ADORA3ABCC1MEN1KMT2A
SCHEMBL16038378 0.88 PDE10A (0.58) ABCG2ADORA3ABCC1MEN1KMT2A
SCHEMBL16039130 0.88 MEN1 (0.62) ABCG2ADORA3ABCC1MEN1KMT2A
SCHEMBL15253806 0.85 ABCG2 (0.57) ABCG2ADORA3ABCC1MEN1KMT2A
SCHEMBL10727060 0.85 ABCG2 (0.50) ABCG2ADORA3ABCC1DHODHMEN1
SCHEMBL16039610 0.84 PRNP (0.47) ABCG2ADORA3ABCC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4639454-A LYMPHOID LEUKEMIA E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-01-27 US claimed
US-20020156050-A1 Carboxamine compounds, methods and compositions for inhibiting PARP activity GUILFORD PHARMACEUTICALS INC. 2002-10-24 US disclosed
US-6395749-B1 Carboxamide compounds, methods, and compositions for inhibiting PARP activity GUILFORD PHARMACEUTICALS INC. 2002-05-28 US disclosed
US-4639454-A LYMPHOID LEUKEMIA E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-01-27 US disclosed
US-4639454-A LYMPHOID LEUKEMIA E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156050-A1 Carboxamine compounds, methods and compositions for inhibiting PARP activity PARP1, PARP3, PARP4 ABCG2 146/4885ADORA3 909/4885ABCC1 1538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.